Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)?

Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? Faheem Tahir Sun, April 12, 2026 at 5:49 PM EDT 2 min read ALLO Allogene Therapeutics, Inc. (NASDAQ: ALLO ) secured a spot on our list of the best penny stocks set to explode . Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? As of April 8, 2026, analyst sentiment toward Allogene Therapeutics, Inc. (NASDAQ:ALLO) remains bullish, with 85% of analysts issuing “Buy” ratings on the stock. The consensus price target of $7.50 implies an upside of 186.26%. On March 13, 2026, Piper Sandler increased its price target from $7 to $8 and kept an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO). The firm stated that investor attention was shifting to the April interim analysis from the ALPHA3 study in first-line consolidation LBCL, while noting a favorable setup for cema-cel to achieve a 25%–30% MRD clearance advantage over observation. This development followed Allogene Therapeutics, Inc. (NASDAQ:ALLO)’s March 12, 2026, Q4 and full-year 2025 results, in which management referred to ALPHA3 as a significant turning point, while also noting that the study may determine whether allogeneic CAR-T can be administered at a biologic-like scale and grow beyond academic centers. Allogene Therapeutics, Inc. (NASDAQ:ALLO) has $258.3 million in cash, cash equivalents, and investments at the end of 2025, extending the company’s runway into Q1 2028, while guiding to $150 million in operating cash expense…